Actively Recruiting
Interest of Late Images for the Assessment of Extensions in 18FDG PET-CT of Muscle-Invasive Bladder Cancers
Led by Hopital Foch · Updated on 2025-11-21
66
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of late-phase 18FDG PET-CT imaging to improve lymph node staging in patients with muscle-invasive bladder tumor (MIBT) at stage 63pT2. This study aims to show whether delayed PET images taken 2.5 hours after radiotracer injection offer better sensitivity compared to the standard images taken at 1 hour. The assessment focuses on areas around the right and left iliac lymph nodes to guide treatment decisions for these patients. Participants will undergo 18FDG PET-CT scans in two phases: the first phase involves a standard scan from head to mid-thigh at 1 hour after injection of the radiotracer and a diuretic, with a CT scan for anatomical details. The second phase consists of additional abdomino-pelvic scans at 2.5 hours post-injection with a low-dose CT scan for correction purposes. Patients will empty their bladder before each scan phase to improve image quality. During the study, patients will receive routine care including fasting and blood glucose checks before imaging. Researchers will compare PET scan findings with lymph node removal results after surgery (if performed) to measure sensitivity. Treatment decisions will be made based on standard PET images, while late images will be analyzed later for sensitivity. Participants may be followed for up to 39 months to assess outcomes related to lymph node staging.
CONDITIONS
Brief Title
Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient 18 years of age or older
- Histologically proven muscle-invasive bladder cancer (stage 63pT2) after bladder resection
- Scheduled for 18FDG PET-CT at H�f4pital Foch nuclear medicine department
- Signed informed consent form
- Affiliated with a health insurance scheme
You will not qualify if you...
- History of pelvic or genitourinary cancer
- Known metastatic disease
- Contraindication to 18FDG PET-CT
- Pregnant or breastfeeding women
- Patients deprived of liberty or under guardianship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Same day
Participants undergo 18FDG PET-CT imaging in two phases to assess bladder cancer extensions.
1 visit (in-person) with imaging at 1 hour and 2.5 hours post radiotracer injection
Trial Site Locations
Total: 1 location
1
Hopital Foch
Suresnes, Île-de-France Region, France, 92150
Actively Recruiting
Research Team
M
MARC BERTAUX, Dr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here